Details
Stereochemistry | ACHIRAL |
Molecular Formula | C9H13N5O |
Molecular Weight | 207.2324 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCCN1C2=NC(N)=NN2C=C(C)C1=O
InChI
InChIKey=UQDVRVNMIJAGRK-UHFFFAOYSA-N
InChI=1S/C9H13N5O/c1-3-4-13-7(15)6(2)5-14-9(13)11-8(10)12-14/h5H,3-4H2,1-2H3,(H2,10,12)
Molecular Formula | C9H13N5O |
Molecular Weight | 207.2324 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://www.ncbi.nlm.nih.gov/pubmed/6302550Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/189873 | https://www.ncbi.nlm.nih.gov/pubmed/15019272
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6302550
Curator's Comment: The description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/189873 | https://www.ncbi.nlm.nih.gov/pubmed/15019272
ICI-63197 is a potent and selective phosphodiesterase IV (PDE 4) inhibitor with potent antidepressant activity. The antidepressant action of ICI-63197 realizes via enhancement of central noradrenergic transmission due to selective inhibition of cAMP phosphodiesterase. ICI 63 197 was investigated in mice for its effectiveness in two classical test models for prediction of clinical antidepressant activity: antagonism of reserpine-induced hypothermia or hypokinesia and potentiation of yohimbine lethality. ICI 63 197 was approximately 15 times more potent than imipramine in antagonizing reserpine-induced hypothermia. The antihypothermic effect of the ICI-63197 occurred at a smaller dose than that of imipramine. In contrast to imipramine, the ICI-63197 reversed reserpine-induced hypokinesia. ICI-63197 approximately, as potent as imipramine in potentiating the lethality of yohimbine. ICI 63 197 was never tested in clinical trials.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093863 Sources: https://www.ncbi.nlm.nih.gov/pubmed/15019272 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/6302550
0.48-29.9 mkM/kg (Male NMRI mic)
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/189873
The rate of acid secretion and mucosal cyclic adenosine 3',5'-monophosphate (cyclic AMP) content have been measured on the same guinea-pig isolated stomach preparation in response to ICI 63197, a potent phosphodiesterase inhibitor. The stomach was divided into two halves along the greater curvature and each half was tied over the end of a short perspex tube, mucosal surface facing the lumen. The muscle coat was not removed. The serosal surface was bathed with a bicarbonate buffered saline and gassed with 95% 2 and 5% CO2 whilst the mucosal surface was bathed with a similar but unbuffered saline gassed with 100% O2. The volume of serosal bathing fluid was 30 ml and the rate of acid secretion was determined by titration with 20 mM NaOH. Following dissection, the preparations were set up in the tissue bath and gassed for 1 h before addition of ICI-63197. The mucosal saline was changed every 15 min and the rate of spontaneous acid secretion determined. After the addition of drug (ICI-63197), acid secretion was measured for four further 15 min periods. The rate associated with the drug was taken as the average of the last two such periods. Tissues were then taken from the bath and placed in ice cold saline before extraction for cyclic AMP assay.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 11:01:18 GMT 2023
by
admin
on
Sat Dec 16 11:01:18 GMT 2023
|
Record UNII |
015G4I43YD
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English |
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
ICI-63197
Created by
admin on Sat Dec 16 11:01:18 GMT 2023 , Edited by admin on Sat Dec 16 11:01:18 GMT 2023
|
PRIMARY | |||
|
27277-00-5
Created by
admin on Sat Dec 16 11:01:18 GMT 2023 , Edited by admin on Sat Dec 16 11:01:18 GMT 2023
|
PRIMARY | |||
|
DTXSID6041391
Created by
admin on Sat Dec 16 11:01:18 GMT 2023 , Edited by admin on Sat Dec 16 11:01:18 GMT 2023
|
PRIMARY | |||
|
248-383-5
Created by
admin on Sat Dec 16 11:01:18 GMT 2023 , Edited by admin on Sat Dec 16 11:01:18 GMT 2023
|
PRIMARY | |||
|
62824
Created by
admin on Sat Dec 16 11:01:18 GMT 2023 , Edited by admin on Sat Dec 16 11:01:18 GMT 2023
|
PRIMARY | |||
|
015G4I43YD
Created by
admin on Sat Dec 16 11:01:18 GMT 2023 , Edited by admin on Sat Dec 16 11:01:18 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |